New Treatment Is Approved for a Variety of Respiratory Infections

Susan Farley
Published Online: Thursday, July 1, 2004

The FDA recently approved telithromycin to treat acute exacerbation of chronic bronchitis, acute bacterial sinusitis, and mild-to-moderate community-acquired pneumonia in patients aged 18 and older. The drug is manufactured by Aventis under the brand name KETEK. According to Paul Iannini, MD, clinical professor of medicine at Yale University, "KETEK's innovative mechanism of action selectively targets common respiratory pathogens, including resistant strains, without significant effects on bacteria not normally involved in RTIs [respiratory tract infections]. This may be an important factor in minimizing the development of antibiotic resistance, a critical public health concern and one that I've seen in my clinical practice."

KETEK was first introduced in Europe, Latin America, and Asia and has been prescribed for >7 million patients. In its clinical trials, subjects taking KETEK reported side effects such as nausea, headache, dizziness, vomiting, and diarrhea.

Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues